0092184
print

Drug Panel 7, Urine - Screen with Reflex to Confirmation/Quantitation

CDASU 7
Example Reports
Negative
Positive

Ordering Recommendation

Useful for general screening in contexts of compliance and/or abuse. A screen with reflex testing is the preferred method for ruling out drug exposure. This test does not distinguish between the delta-8 and delta-9 forms of THC or their metabolites.

New York DOH Approval Status

This test is New York state approved.

Specimen Required

Patient Preparation
Collect

Random urine.

Specimen Preparation

Transfer 8 mL urine with no additives or preservative to ARUP Standard Transport Tubes. (Min: 4 mL)

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

Specimens exposed to repeated freeze/thaw cycles.

Remarks
Stability

Ambient: 1 week; Refrigerated: 1 month; Frozen: 1 month

Methodology

Qualitative Enzyme Multiplied Immunoassay Technique (EMIT)/Quantitative Gas Chromatography-Mass Spectrometry (GC-MS)/Quantitative Liquid Chromatography-Tandem Mass Spectrometry

Performed

Sun-Sat

Reported

1-4 days

Reference Interval

Drugs Covered and Cutoff Concentrations
Drugs/Drug Classes
 Screen
THC (Cannabinoids) 50 ng/mL
Cocaine 150 ng/mL
Opiates 300 ng/mL
Oxycodone 100 ng/mL
Phencyclidine 25 ng/mL
Amphetamines 300 ng/mL
MDMA (Ecstasy) 500 ng/mL
Barbiturates 200 ng/mL
Benzodiazepines 200 ng/mL

Interpretive Data

The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration at which the screening test can detect a drug or metabolite varies within a drug class. Specimens for which drugs or drug classes are detected by the screen are reflexed to a second, more specific technology (GC/MS and/or LC-MS/MS). The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

For medical purposes only; not valid for forensic use.

Oxycodone results are reported with the opiates results. MDMA results are reported with the amphetamines results.

Compliance Category

FDA

Note

If the specimen screens positive, then Confirmation/Quantitation by GC/MS and/or LC-MS/MS will be added to confirm result. Additional charges apply.

Hotline History

View Hotline History

 

Hotline History

Date of Change
Test Name Change
Methodology
Performance/Reported Schedule
Specimen Requirements
Reference Interval
Interpretive Data
Note
CPT Code
Component Change
Other Interface Change
New Test
Inactive
05/15/2023
X
N/A

CPT Codes

80307; if reflexed, add 80325; 80345; 80346; 80349; 80353; 80359; 80361; 80365; 83992 (Reflexed Alt Code: G0480 )

Are you an ARUP Client? Click here for your pricing.

Components

Component Test Code* Component Chart Name LOINC
0090386 Creatinine, Urine 2161-8
0090407 CDASU 7 Comments 77202-0
0092191 Amphetamines, Urn, Screen 19261-7
0092192 Cocaine, Urn, Screen 19359-9
0092193 Opiates, Urn, Screen 19300-3
0092194 Phencyclidine, Urn, Screen 19659-2
0092195 THC, Urn, Screen 19292-2
0092196 Barbiturates, Urn, Screen 19270-8
0092197 Benzodiazepines, Urn, Screen 14316-4
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • Benzodiazepines, Urine
  • Cocaine, Urine
  • Creatinine, Urine
  • Pain Management
  • Phencyclidine, Urine
  • Marijuana, Urine
  • Opiates, Urine
  • Barbiturates, Urine
  • Amphetamines, Urine
Drug Panel 7, Urine - Screen with Reflex to Confirmation/Quantitation